Back to Results

A Phase 1/2 study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Subjects with ALK+ Advanced or Metastatic NSCLC

Study

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Ross Camidge,  MD, PhD

Ross Camidge, MD, PhD

Study ID

Protocol Number: 21-3413

More information available at ClinicalTrials.gov: NCT04849273

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers